The insulin and insulin-like growth factor receptor family in neoplasia: an update.

Nature Reviews. Cancer
Michael Pollak

Abstract

Although several early phase clinical trials raised enthusiasm for the use of insulin-like growth factor I receptor (IGF1R)-specific antibodies for cancer treatment, initial Phase III results in unselected patients have been disappointing. Further clinical studies may benefit from the use of predictive biomarkers to identify probable responders, the use of rational combination therapies and the consideration of alternative targeting strategies, such as ligand-specific antibodies and receptor-specific tyrosine kinase inhibitors. Targeting insulin and IGF signalling also needs to be considered in the broader context of the pathophysiology that relates obesity and diabetes to neoplasia, and the effects of anti-diabetic drugs, including metformin, on cancer risk and prognosis. The insulin and IGFI receptor family is also relevant to the development of PI3K-AKT pathway inhibitors.

Associated Clinical Trials

References

Nov 8, 1979·The New England Journal of Medicine·D A LangR C Turner
Dec 1, 1976·Proceedings of the National Academy of Sciences of the United States of America·C K OsborneM E Lippman
Dec 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·C SellR Baserga
May 23, 1997·Science·L ZhangK W Kinzler
Dec 26, 2001·Journal of the National Cancer Institute·Y LuM Pollak
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pamela J GoodwinNicky Hood
Apr 12, 2002·Trends in Endocrinology and Metabolism : TEM·Robert S Garofalo
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rebecca A BetenskyJ Gregory Cairncross
Dec 6, 2002·Endocrine Reviews·Sue M Firth, Robert C Baxter
Apr 25, 2003·The New England Journal of Medicine·Eugenia E CalleMichael J Thun
Oct 10, 2003·American Journal of Physiology. Endocrinology and Metabolism·Michelangela BarbieriGiuseppe Paolisso
Mar 31, 2004·Cancer Cell·Carlos García-EcheverríaFrancesco Hofmann
Apr 8, 2004·Journal of the National Cancer Institute·Jing MaMeir J Stampfer
Jul 2, 2004·Nature Reviews. Cancer·Michael N PollakSusan E Hankinson
Aug 19, 2004·Cancer·Sally W VernonRichard B Warnecke
Nov 20, 2004·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Pierre De Meyts
Feb 3, 2006·Cancer Research·Kathryn E O'ReillyNeal Rosen
Oct 26, 2006·Cancer Research·Mahvash ZakikhaniMichael Pollak
Dec 13, 2006·The American Journal of Clinical Nutrition·Luigi FontanaJohn O Holloszy
Aug 30, 2007·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·I Hernández-FisacJ Tamarit-Rodriguez
Nov 29, 2007·Journal of the National Cancer Institute·Vasundara VenkateswaranMichael Pollak
Dec 7, 2007·American Journal of Epidemiology·Samy Suissa
May 10, 2008·Nature Biotechnology·Jim Kling
May 13, 2008·Endocrine-related Cancer·Carolyn AlgireMichael Pollak
Sep 12, 2008·The Prostate·Michael E CoxMichael Pollak
Nov 26, 2008·Nature Reviews. Cancer·Michael Pollak

❮ Previous
Next ❯

Citations

Jul 4, 2013·Cancer Causes & Control : CCC·Claudia BeckerMichael Bodmer
Oct 12, 2012·Journal of Mammary Gland Biology and Neoplasia·Yuzhe Yang, Douglas Yee
Mar 5, 2013·Current Diabetes Reports·Mark R Goldstein, Luca Mascitelli
Mar 19, 2013·European Journal of Pharmacology·Christos V Rizos, Moses S Elisaf
Jul 23, 2013·The Journal of Steroid Biochemistry and Molecular Biology·Paul ThelenDana Seidlová-Wuttke
Jan 11, 2013·Nature·John G MentingMichael C Lawrence
May 23, 2012·Proceedings of the National Academy of Sciences of the United States of America·Ola LarssonNahum Sonenberg
Sep 19, 2012·Proceedings of the National Academy of Sciences of the United States of America·Grace E BerryhillRussell C Hovey
Nov 29, 2012·Proceedings of the National Academy of Sciences of the United States of America·Huiyuan ZhengLeonard Girnita
Aug 28, 2013·Proceedings of the National Academy of Sciences of the United States of America·Yong PengCarlo M Croce
Sep 4, 2013·The Journal of Clinical Investigation·Michael Pollak
May 22, 2013·BMC Cancer·Marieke L KuijjerAnne-Marie Cleton-Jansen
Nov 15, 2012·Journal of Translational Medicine·Juan E Puche, Inma Castilla-Cortázar
Apr 17, 2013·BMC Biology·D Grahame Hardie, Dario R Alessi
Oct 12, 2012·Molecular Endocrinology·Stephen D Hursting
Feb 6, 2013·PloS One·Frank J CalzonePedro J Beltran
Jul 26, 2014·PloS One·Suren SarkissyanJaydutt V Vadgama
Mar 7, 2014·Drug Design, Development and Therapy·Mengna ChiJiezhong Chen
Dec 5, 2012·ISRN Endocrinology·Edoardo Mannucci
Dec 19, 2013·International Journal of Endocrinology and Metabolism·Carlo Maria RotellaEdoardo Mannucci
Jul 24, 2014·World Journal of Surgical Oncology·Yun Shin ChunMargaret Von Mehren
Apr 2, 2013·Trends in Pharmacological Sciences·Antoine Dufour, Christopher M Overall
Nov 15, 2013·Journal of Carcinogenesis·Sneha SundaramLiza Makowski
Oct 8, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yuanting XiaoJin Zhang
Jan 5, 2014·Cancer Causes & Control : CCC·Leah BensimonLaurent Azoulay
Nov 6, 2013·Gynecologic Oncology·Nicole S NevadunskyMark H Einstein
May 4, 2013·Biochimica Et Biophysica Acta·Mahasin A OsmanEnrique Rodriguez-Boulan
Jan 8, 2013·Targeted Oncology·A C M van de LuijtgaardenW T A van der Graaf
Jun 12, 2014·Cancer Chemotherapy and Pharmacology·Lei ChengXiao-Ping Qian

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.